HealthMindr App to Increase Pre-exposure Prophylaxis (PrEP) Uptake and Retention Among Men Who Have Sex With Men (MSM)
Status: | Not yet recruiting |
---|---|
Conditions: | HIV / AIDS |
Therapuetic Areas: | Immunology / Infectious Diseases |
Healthy: | No |
Age Range: | 18 - 34 |
Updated: | 3/8/2019 |
Start Date: | April 2019 |
End Date: | May 2022 |
Contact: | Patrick Sullivan, DVM PhD |
Email: | pssulli@emory.edu |
Phone: | 404-727-2038 |
Theoretically Based Mobile App (HealthMindr) to Increase Pre-exposure Prophylaxis (PrEP) Uptake and Retention Among Men Who Have Sex With Men (MSM)
This study is a randomized controlled clinical trial of a theoretically based mobile app,
HealthMindr, to increase pre-exposure prophylaxis (PrEP) uptake among men who have sex with
men (MSM) to prevent human immunodeficiency virus (HIV). Participants in the intervention arm
will receive access to the HealthMindr app, with information about PrEP and other HIV
prevention methods in addition to provider locators. Participants randomized to the control
arm will receive standard of care. The primary aim for this study is to assess PrEP uptake in
the intervention arm compared to the control arm.
HealthMindr, to increase pre-exposure prophylaxis (PrEP) uptake among men who have sex with
men (MSM) to prevent human immunodeficiency virus (HIV). Participants in the intervention arm
will receive access to the HealthMindr app, with information about PrEP and other HIV
prevention methods in addition to provider locators. Participants randomized to the control
arm will receive standard of care. The primary aim for this study is to assess PrEP uptake in
the intervention arm compared to the control arm.
MSM are disproportionately impacted in terms of HIV prevalence and incidence. Electronically
delivered or supported prevention services are effective, are acceptable to MSM, and will
likely reach heavily impacted men. The study is based on the premise that providing, through
a mobile phone app, self-directed PrEP information; periodic behavioral screenings to
identify HIV risk and PrEP indication objectively; referral to PrEP providers with
directions; and related prevention services will increase the uptake of PrEP among at risk,
HIV negative MSM to a greater extent than standard of care referrals to existing resources.
The study will examine the effectiveness of the HealthMindr app to increase uptake of PrEP
among MSM. The study will enroll 657 men across the three sites - the metropolitan
statistical areas (MSA) of Atlanta, Georgia (GA), Jackson, Mississippi (MS), and Washington,
D.C. - into a randomized controlled trial. Participants in the intervention arm will receive
access to the HealthMindr app and men in the control arm will receive standard of care HIV
prevention information. PrEP uptake will be assessed during follow-up by self-report at
months 3, 6, 9, and 12. Self-report will be confirmed by laboratory testing for the presence
of tenofovir diphosphate (TFV-DP) and/or photograph of PrEP prescription or bottle.
At the beginning of the study, all participants will download a study mobile app. After
completing a baseline survey, participants will be randomized to the intervention or control
arm. For participants assigned to the intervention arm, additional app content will become
available. This content will include information about basic prevention services (HIV test
planning and test locators; risk assessment; HIV treatment locators; and condom, HIV test
kit, and at-home sexually transmitted infection (STI) specimen collection kit distribution)
plus monthly PrEP eligibility assessments, PrEP provider locator, enhanced information about
PrEP, and referrals to local PrEP navigators. The app also provides links to health insurance
exchanges, where men can seek health insurance or assistance to help cover PrEP costs. The
control arm will be referred to existing online PrEP and HIV prevention information.
Participants in the control arm will access the control version of the app that contains
elements pertinent to their participation in the research study.
Additional follow-up surveys will be conducted at 3, 6, 9, and 12 months and participants
will also complete monthly assessments. The monthly assessments will assess indications for
PrEP and PrEP uptake (intervention arm) and other health-related behaviors (control arm).
Participants reporting PrEP initiation will be asked to submit a dried blood spot
self-collection kit to allow for measurement of tenofovir diphosphate (TFV-DP) levels and/or
upload a photo of their PrEP prescription bottle to verify PrEP uptake.
delivered or supported prevention services are effective, are acceptable to MSM, and will
likely reach heavily impacted men. The study is based on the premise that providing, through
a mobile phone app, self-directed PrEP information; periodic behavioral screenings to
identify HIV risk and PrEP indication objectively; referral to PrEP providers with
directions; and related prevention services will increase the uptake of PrEP among at risk,
HIV negative MSM to a greater extent than standard of care referrals to existing resources.
The study will examine the effectiveness of the HealthMindr app to increase uptake of PrEP
among MSM. The study will enroll 657 men across the three sites - the metropolitan
statistical areas (MSA) of Atlanta, Georgia (GA), Jackson, Mississippi (MS), and Washington,
D.C. - into a randomized controlled trial. Participants in the intervention arm will receive
access to the HealthMindr app and men in the control arm will receive standard of care HIV
prevention information. PrEP uptake will be assessed during follow-up by self-report at
months 3, 6, 9, and 12. Self-report will be confirmed by laboratory testing for the presence
of tenofovir diphosphate (TFV-DP) and/or photograph of PrEP prescription or bottle.
At the beginning of the study, all participants will download a study mobile app. After
completing a baseline survey, participants will be randomized to the intervention or control
arm. For participants assigned to the intervention arm, additional app content will become
available. This content will include information about basic prevention services (HIV test
planning and test locators; risk assessment; HIV treatment locators; and condom, HIV test
kit, and at-home sexually transmitted infection (STI) specimen collection kit distribution)
plus monthly PrEP eligibility assessments, PrEP provider locator, enhanced information about
PrEP, and referrals to local PrEP navigators. The app also provides links to health insurance
exchanges, where men can seek health insurance or assistance to help cover PrEP costs. The
control arm will be referred to existing online PrEP and HIV prevention information.
Participants in the control arm will access the control version of the app that contains
elements pertinent to their participation in the research study.
Additional follow-up surveys will be conducted at 3, 6, 9, and 12 months and participants
will also complete monthly assessments. The monthly assessments will assess indications for
PrEP and PrEP uptake (intervention arm) and other health-related behaviors (control arm).
Participants reporting PrEP initiation will be asked to submit a dried blood spot
self-collection kit to allow for measurement of tenofovir diphosphate (TFV-DP) levels and/or
upload a photo of their PrEP prescription bottle to verify PrEP uptake.
Inclusion Criteria:
- Cisgender male
- 18-34 years of age (inclusive)
- Resides in one of the 3 study MSAs
- Intends to remain in study area for duration of the trial
- Owns a smartphone
- Able to read and understand English without assistance
- Reports having anal sex with a man in the past 6 months
- Reports being HIV negative or never tested for HIV
- Willingness to download mobile app
Exclusion Criteria:
- Cisgender female, transgender male, transgender female, gender non-conforming
- Currently on PrEP
- < 18 or >34 years of age
- Self-reported HIV positive
- Resides outside of the 3 MSAs or plans to move outside study MSA within 12 months
- Current participant in another HIV prevention study
We found this trial at
3
sites
Washington, District of Columbia 20052
Principal Investigator: Amanda D Castel, MD, MPH
Phone: 202-994-8325
Click here to add this to my saved trials
201 Dowman Dr
Atlanta, Georgia 30303
Atlanta, Georgia 30303
(404) 727-6123
Principal Investigator: Patrick Sullivan, DVM, PhD
Phone: 404-727-2038
Emory University Emory University, recognized internationally for its outstanding liberal artscolleges, graduate and professional schools,...
Click here to add this to my saved trials
2500 N State St
Jackson, Mississippi 39216
Jackson, Mississippi 39216
(601) 984-1000
Principal Investigator: Leandro Mena, MD, MPH
Phone: 601-984-5560
University of Mississippi Medical Center The University of Mississippi Medical Center, located in Jackson, is...
Click here to add this to my saved trials